Human CYPs involved in drug metabolism: structures, substrates and binding affinities
暂无分享,去创建一个
[1] D A Smith,et al. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.
[2] G. Loew,et al. Homology modeling and substrate binding study of human CYP2C9 enzyme , 1999, Proteins.
[3] D. Lewis,et al. Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. , 2008, Expert opinion on drug metabolism & toxicology.
[4] Yuko Ito,et al. Chapter 1:Cytochrome P450 Structure and Function: An Evolutionary Perspective , 2008 .
[5] D. Lewis,et al. Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily. , 2006, Current drug metabolism.
[6] Laura Lowe Furge,et al. Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction , 2006, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.
[7] J. M. Pratt,et al. The P450 catalytic cycle and oxygenation mechanism. , 1998, Drug metabolism reviews.
[8] C. Ioannides. Cytochromes P450 : role in the metabolism and toxicity of drugs and other xenobiotics , 2008 .
[9] D. Lewis,et al. Enzyme-Substrate Binding Interaction Energies and Their Application to the Cytochrome P450 System , 2008 .
[10] Corwin Hansch,et al. QSAR of Cytochrome P450 , 2004, Drug metabolism reviews.
[11] S. Shaik,et al. Computational Approaches to Cytochrome P450 Function , 2005 .
[12] G. Cruciani,et al. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.
[13] Lars Carlsson,et al. State-of-the-art Tools for Computational Site of Metabolism Predictions: Comparative Analysis, Mechanistical Insights, and Future Applications , 2007, Drug metabolism reviews.
[14] S. Ekins,et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.
[15] M. J. Coon,et al. Multiple mechanisms and multiple oxidants in P450-catalyzed hydroxylations. , 2003, Archives of biochemistry and biophysics.
[16] C. Hansch,et al. QSAR of P450 oxidation: on the value of comparing kcat and km with kcat/km. , 1996, Drug metabolism reviews.
[17] Maurice Dickins,et al. Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.
[18] S. Ekins,et al. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[19] C. Hansch,et al. Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.
[20] Gordon C K Roberts,et al. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. , 2004, Journal of medicinal chemistry.
[21] Yuko Ito,et al. Structural modelling of the human drug-metabolizing cytochromes P450. , 2006, Current medicinal chemistry.
[22] D. Putt,et al. AN INCREDIBLY FAST APPARENT OXYGEN REBOUND RATE CONSTANT FOR HYDROCARBON HYDROXYLATION BY CYTOCHROME P-450 ENZYMES , 1995 .
[23] G J Kleywegt,et al. Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.
[24] F. Guengerich,et al. Human cytochrome P-450 enzymes. , 1992, Life sciences.
[25] Yuko Ito,et al. Analysis of CYP2D6 substrate interactions by computational methods. , 2008, Journal of molecular graphics & modelling.
[26] M. Levitt,et al. Aromatic Rings Act as Hydrogen Bond Acceptors , 2022 .
[27] Slobodan Petar Rendic. Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.
[28] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[29] S. Ekins,et al. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.
[30] F. Guengerich,et al. Substrate binding to cytochromes P450 , 2008, Analytical and bioanalytical chemistry.
[31] F. Guengerich. Cytochrome p450 and chemical toxicology. , 2008, Chemical research in toxicology.
[32] G H Loew,et al. Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes , 1999, Proteins.
[33] D. Lewis,et al. 57 varieties: the human cytochromes P450. , 2004, Pharmacogenomics.
[34] D. Lewis. Guide to Cytochromes P450 : structure and function , 2001 .
[35] D. Lewis,et al. Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: The importance of compound lipophilicity , 2007, Journal of enzyme inhibition and medicinal chemistry.
[36] Stewart B Kirton,et al. In silico methods for predicting ligand binding determinants of cytochromes P450. , 2004, Current topics in medicinal chemistry.
[37] S. Ekins,et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.
[38] Johann Gasteiger,et al. Ligand-Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates , 2007, J. Chem. Inf. Model..
[39] D. Lewis,et al. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. , 2003, Current medicinal chemistry.
[40] D. Lewis,et al. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[41] D. Lewis. Hydrogen Bonding in Human P450-Substrate Interactions: A Major Contribution to Binding Affinity , 2004, TheScientificWorldJournal.